CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Contribution in Pathology Diagnosis and Molecular Biology

• Conditions: Image-Guided Biopsy - Carcinoma, Bronchogenic / Diagnosis- Outpatients
• Interventions: Procedure: CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer

• Registration Number: NCT03386916
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

In case of primary lung cancer, bone metastases biopsy can be done in initial diagnosis or follow-up.

Nevertheless, any study focus on rentability and biopsy complications of lytic bone lesion for the context of lung cancer.

This study aims to demonstrate that CT scan guide percutaneous biopsy of lytic bone lesion help to anatomopathologic diagnosis and molecular biology with a low complication rate inasmuch a lung cancer is suspected.

This study is observational, retrospective, one center

Detailed Description

Current progress in thoracic oncology require to be able to carry out analysis by molecular biology. So biopsies are done several times during cancer progression. But risk is high for a lung biopsy with enough sample, so a CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer can be an alternative.

In case of primary lung cancer, bone metastases biopsy can be done in initial diagnosis or follow-up. But this contribution in diagnostic (anatomopathologic an molecular biology) is poorly understood. It is demonstrated that to sample on lytic bone lesion have a failure rate lower than on calcified osseous lesion. Nevertheless, any study focus on rentability and biopsy complications of lytic bone lesion for the context of lung cancer.

this study aims to demonstrate that CT scan guide percutaneous biopsy of lytic bone lesion help to anatomopathologic diagnosis and molecular biology with a low complication rate inasmuch a lung cancer is suspected.

This study is observational, retrospective, descriptive, one-center Patient's records selection will be done by keyword search on the CHU Grenoble Alpes radiology software. Only records with bone biopsy register between January 2010 and June 2017 will be included.

Study Timeline

• Study Start: 2010-01
• Primary Completion: 2017-06
• Status Verified: 2017-12
• Study First Submitted: 2017-12-12
• Study First Submitted QC: 2017-12-28
• Last Update Submitted: 2017-12-28
• Study First Posted: 2017-12-29
• Last Update Posted: 2017-12-29
• Study Completion: 2018-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• CT scan guide percutaneous biopsy of lytic bone metastases
• register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
• Patient who have a clinical context of lung cancer with bone metastases

Exclusion Criteria

• Person deprived of liberty by judicial order
• Opposition expressed by patient

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patient with a CT scan guide percutaneous biopsy of lytic bone	CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer	Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017

Primary Outcome Measures

Name	Time	Method
Rentability of biopsy of lytic bone lesion in anatomopathologic analysis	Analysis between january 2018-september 2018	Rentability of biopsy of lytic bone lesion = 100x (number of sample wich analysed by anatomopathologic /total number of biopsy of lytic bone lesion done)

Secondary Outcome Measures

Name	Time	Method
Rentability of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed	Analysis between january 2018-september 2018	Rentability of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed; - =100x (number of sample wich analysed by molecular biology /total number of biopsy of lytic bone lesion sent to molecular biology analysis)
Cell quality in sample of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed	Analysis between january 2018-september 2018	Cell quality in sample of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed; * average percentage of tumour cells in samples
Complication rate linked to gesture of biopsy of lytic bone lesion	Analysis between january 2018-september 2018	Complication rate linked to gesture of biopsy of lytic bone lesion and descriptive analysis
Impact assessement of biopsy of lytic bone lesion on patient care	Analysis between january 2018-september 2018	Modification of management of lung cancer between before biopsy and after biopsy results